

Johnson & Johnson's spinoff Kenvue supports biomarkers screening for skin disorders in children

06 July 2023 | News

Emerging potential of biomarker screenings for early identification of children who are at risk of developing atopic dermatitis



US-based pharmaceutical firm Johnson & Johnson's consumer healthcare spinoff Kenvue has supported a study to investigate whether certain markers of skin health could predict risk of having atopic or eczema prone skin, in children from birth.

The study found that specific markers of skin inflammation tended to be higher in children who later developed atopic dermatitis. This advancement in health care suggests that skin health markers might have a place in clinical practice to be used to predict the progression of the condition. Additionally, these markers may help identify individuals who could benefit from early measures, such as using moisturisers to maintain skin health.

Keshan Gunasinghe, Head of APAC R&D for Kenvue said, "This emergent study that we have presented at the World Congress of Dermatology helps us understand skin surface markers for children at risk of developing dry, itchy, sensitive skin conditions (which may or may not be related to atopic or eczema prone skin). These insights will be pivotal as we continue delivering innovative and trusted paediatric skin health solutions built on strong scientific evidence through close collaboration with the paediatric dermatology community."

In India, 57% parents are likely to use a moisturiser, before symptoms appeared, even if they suspected their child was high-risk of developing sensitive skin conditions. Just 26% of the parents were either unsure or unlikely to use moisturiser to delay the onset of eczema like symptoms. In fact, over 55% parents are unsure about the significance of preventative measure & the potential cost associated with prevention approach.